A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease

Summary

This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of orally administered AVE8112 in patients with Parkinson's Disease (PD).

Timeline

Start

2013-01

Primary completion

2015-06

Completion

2015-06

Outcome

Outcome not reported

Stopped: “First milestone was not met.”

Drugs

Indications